Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/anie.201201849 | DOI Listing |
Gels
December 2024
Multimaterials and Interfaces Laboratory (LMI), CNRS UMR 5615, University Claude Bernard Lyon 1, University of Lyon, 6 rue Victor Grignard, 69622 Villeurbanne, France.
Temporomandibular disorders (TMD) are a public health problem that affects around 12% of the global population. The treatment is based on analgesics, non-steroidal anti-inflammatory, corticosteroids, anticonvulsants, or arthrocentesis associated with hyaluronic acid-based viscosupplementation. However, the use of hyaluronic acid alone in viscosupplementation does not seem to be enough to regulate the intra-articular inflammatory process.
View Article and Find Full Text PDFMaterials (Basel)
November 2024
Laboratoire des Multimatériaux et Interfaces UMR CNRS 5615, Universite Claude Bernard Lyon 1, 6 rue Victor Grignard, 69622 Villeurbanne, France.
Hydrogels are promising scaffolds for tissue regeneration, and borosilicate glass particles have demonstrated potential in enhancing the biological behaviour of dental pulp cells. However, the specific morphological characteristics of dental lesions and the diverse requirements of dental tissues require biocompatible, bioactive, and shapeable scaffolds. This study aimed to evaluate the in vitro biological behaviour of human gingival fibroblasts (HGFs) in contact with an experimental aluminum-free borosilicate glass-functionalized hydrogel.
View Article and Find Full Text PDFBeilstein J Org Chem
November 2024
Merck Electronics KGaA, Frankfurter Str. 250, D-64293 Darmstadt, Germany.
Biofabrication
November 2024
Laboratory of Tribology and System Dynamics,, UMR-CNRS 5513-Ecole Centrale Lyon, Ecully, Auvergne-Rhône-Alpes FR 69134, France.
Carbohydr Polym
January 2025
Universite Claude Bernard Lyon 1, INSA de Lyon, Universite Jean Monnet, CNRS, Ingénierie des Matériaux Polymères (IMP), UMR 5223, 15 bd Latarjet, F-69622 Villeurbanne, France. Electronic address:
In this study, a chitosan derivative with strong iron (III) chelating capabilities was developed by grafting the Deferoxamine (DFO) chelator to achieve a substitution degree of 3.8 ± 0.2 %.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!